We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

By LabMedica International staff writers
Posted on 23 Apr 2025
Print article
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures to selectively deliver fluorescent imaging agents to pancreatic cancer cells without affecting normal cells.

The research, conducted by scientists at the University of Illinois Urbana-Champaign (Champaign, IL, USA) and Purdue University (West Lafayette, IN, USA), revealed that DNA origami structures, which are engineered to carry packets of imaging dye, can selectively target human KRAS mutant cancer cells. These cells are present in approximately 95% of pancreatic cancer cases. DNA, being a long double-stranded molecule, is particularly suited for folding into nanoscale scaffolds capable of holding molecules—in this case, fluorescent dyes—at precise locations to form new, synthetic molecular structures.

In their experiments, the researchers created 3D models of pancreatic cancer using "tumoroids" and microfluidic systems that replicate the complex tumor microenvironment. These microfluidic tumor-stroma models were designed to reduce reliance on animal tissue and enhance the potential for translating these findings to human clinical applications. To test how effectively the DNA origami structures were taken up by cancerous tissues, the researchers applied the dye-packed DNA structures to the tumor models and monitored their movement using fluorescence imaging. They further tested the distribution of these DNA origami packets in a more biologically relevant environment by administering them to mice implanted with human pancreatic tumor tissue.

The team experimented with various DNA origami shapes, including tube-shaped and tile-shaped molecules. The results, published in the journal Advanced Science, showed that tube-shaped molecules measuring approximately 70 nanometers in length and 30 nanometers in diameter, as well as smaller versions about 6 nanometers in length and 30 nanometers in diameter, exhibited the highest uptake by pancreatic cancer tissue, without being absorbed by surrounding non-cancerous tissue. In contrast, larger tube-shaped molecules and all tile-shaped molecules showed less effective results. Looking ahead, the researchers plan to explore the use of DNA origami structures loaded with chemotherapy drugs for targeted delivery to cancer cells, further minimizing impact on normal cells.

“This research highlights not only the potential for more accurate cancer imaging, but also selective chemotherapy delivery, a significant advancement over current pancreatic ductal adenocarcinoma treatments,” said Bumsoo Han, a mechanical science and engineering professor at University of Illinois Urbana-Champaign. “The current process of cancerous tissue removal through surgical resection can be improved greatly by more accurate imaging of tumor margins.”

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.